Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Recombinant KRT8 anticorps

Cet anticorps Lapin Monoclonal détecte spécifiquement KRT8 dans WB, IHC, IF et FACS. Il présente une réactivité avec des échantillons de Humain.
N° du produit ABIN7863062
639,45 €
Plus frais de livraison 40,00 € et TVA
Destination: France
Envoi sous 6 à 10 jours ouvrables

Aperçu rapide pour Recombinant KRT8 anticorps (ABIN7863062)

Antigène

Voir toutes KRT8 Anticorps
KRT8 (Keratin 8 (KRT8))

Type d'anticorp

Recombinant Antibody

Reactivité

  • 342
  • 92
  • 90
  • 69
  • 68
  • 66
  • 65
  • 16
  • 14
  • 11
  • 9
  • 7
  • 4
  • 3
  • 2
  • 1
  • 1
  • 1
Humain

Hôte

  • 178
  • 176
  • 3
Lapin

Clonalité

  • 215
  • 139
  • 1
Monoclonal

Conjugué

  • 199
  • 26
  • 17
  • 8
  • 8
  • 7
  • 7
  • 7
  • 7
  • 7
  • 7
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
Cet anticorp KRT8 est non-conjugé

Application

  • 256
  • 186
  • 136
  • 104
  • 73
  • 56
  • 52
  • 41
  • 41
  • 39
  • 35
  • 25
  • 23
  • 5
  • 4
  • 2
  • 2
  • 2
  • 1
  • 1
Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Flow Cytometry (FACS)

Clone

KRT8-4067R
  • Fonction

    Recombinant Cytokeratin 8 (KRT8) Antibody

    Specificité

    Epitope of this MAb is located between aa343-357. Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular ( ring-like, perinuclear ) from ductal ( peripheral-predominant ) carcinoma of the breast.

    Purification

    200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G.

    Immunogène

    Keratin preparation from a human carcinoma

    Isotype

    IgG, kappa
  • Indications d'application

    Optimal working dilution should be determined by the investigator.

    Restrictions

    For Research Use only
  • Concentration

    200 μg/mL

    Buffer

    Prepared in 10 mM PBS with 0.05 % BSA & 0.05 % azide.

    Agent conservateur

    Sodium azide

    Précaution d'utilisation

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Stock

    4 °C

    Stockage commentaire

    Antibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

    Date de péremption

    24 months
  • Antigène

    KRT8 (Keratin 8 (KRT8))

    Autre désignation

    Cytokeratin 8

    Sujet

    CARD2, CK8, CYK8, CYKER, Cytokeratin Endo A, DreK8, EndoA, K2C8, K8, Keratin 8, Krt 2.8, KRT8, Type-II Keratin Kb8

    Colon, HCT-116, HeLa or A431 cells. Human skin, lung or breast carcinoma., MCF-7, Intestine, Stomach.

    Poids moléculaire

    52.5kDa

    ID gène

    3856

    UniProt

    P05787
Vous êtes ici:
Chat with us!